智通财经APP获悉，科济药业-B(02171)再涨超4%，截至发稿，涨4.36％，报19.14港元，成交额3584.58万港元。
消息面上，科济药业宣布，计划在未来150个香港交易日内，回购不超过公司已发行股份总数1%的股份。该计划需获得股东大会批准，并将在公开市场上执行，旨在提升股东价值及优化资本结构。
德邦证券指出，科济药业首款产品泽沃基奥仑赛注射液（CT053，BCMA），显示出具有竞争力的有效性和安全性，于2024年2月获NMPA批准上市。公司另一款产品舒瑞基奥仑赛注射液（CT041）为全球潜在同类首创的Claudin 18.2 CAR-T，中国胃癌（3L+）确证性II期临床试验已完成入组，预计将于2025年上半年递交NDA。美股通用型CART研发公司Allogene Therapeutics验证了通用型CART技术的不断突破，科济药业特异性CAR-T技术有较大潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.